News und Analysen

Investors face a choice between hardware and software dominance as Advanced Micro Devices (NASDAQ:AMD) and AppLovin (NASDAQ:APP) compete for capital in an increasingly artificial intelligence-driven

AST SpaceMobile (NASDAQ: ASTS), a developer of low Earth orbit (LEO) satellites, went public through a merger with a special purpose acquisition company on April 7, 2021. It started trading at

Inference has become the fastest-growing part of the artificial intelligence (AI) infrastructure market, and Bloomberg Intelligence projects it will double the size of the AI training market by

The U.S. Bureau of Labor Statistics recently released the July 2026 Jobs Report. It was much weaker than anticipated, with hiring weakening considerably, as employers cut 23,000 jobs during the

Investors often weigh high-margin drug developers against massive healthcare service providers when building a portfolio. Choosing between AbbVie (NYSE:ABBV) and CVS Health (NYSE:CVS) requires

Pfizer (NYSE: PFE) reported its second-quarter results on Aug.4. The company's performance was pretty good. Revenue increased 3% year over year to about $15 billion. That doesn't sound particularly

AT&T (NYSE: T) appears to face a significant threat from Space Exploration Technologies (NASDAQ: SPCX). COO Gwynne Shotwell announced that SpaceX's connectivity segment, Starlink, will compete with

AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two top healthcare stocks that pay above-average dividends. Both may be compelling options for investors to consider.

AbbVie pays a more modest yield

AbbVie (NYSE: ABBV) is aiming high with its $10.6 billion planned purchase of Apogee Therapeutics (NASDAQ: APGE). The deal, pending regulatory approvals, is expected to close in the third quarter.

The summer investing months are typically known for their sleepiness, with action picking up again in the final months to close out the year. But August is also a great time to do some portfolio

Solomon Moshkevich, president of clinical diagnostics at Natera, Inc. (NASDAQ:NTRA), sold 3,410 shares of common stock on August 3, according to an SEC Form 4 filing.

Transaction value based on SEC

Executive Chairman Matthew Rabinowitz reported a sale of 2,000 shares of Natera, Inc. (NASDAQ:NTRA) in a recent SEC Form 4 filing.

Transaction value based on SEC Form 4 weighted average sale price

Eli Lilly (NYSE: LLY) had a fine start to the trading week. On Monday, its stock rose by almost 4% on news that a key European regulator had approved one of its star medications. That also provided

Matthew Rabinowitz, the executive chairman of Natera, Inc. (NASDAQ:NTRA), sold 731 shares of common stock at $267.99 per share on August 3, according to an SEC Form 4 filing.

Transaction value based

Michael Burkes Brophy, the chief financial officer of Natera, Inc. (NASDAQ:NTRA), sold 795 shares of common stock at $271.74 per share in transactions executed on August 3 and August 4, according to

Jonathan Sheena, a co-founder of Natera, Inc. (NASDAQ:NTRA), sold 9,150 shares of common stock at $315.66 per share on August 7, according to an SEC Form 4 filing.

Transaction value based on SEC

Dividend cuts don't typically happen without warning. Investors can see a business that's in trouble. Perhaps it's in the midst of a turnaround, it's restructuring, or its profits are simply

Leading healthcare company AbbVie (NYSE: ABBV) is coming off a strong quarter. Last month, the Illinois-based business posted yet another round of solid quarterly results, putting on display its